Literature DB >> 8428349

Prostatic microcarcinomas in relation to cancer origin and the evolution to clinical cancer.

J E McNeal1.   

Abstract

BACKGROUND: In the prostate there is a uniquely high prevalence of microcarcinomas relative to larger cancers. The probability of metastasis has been found to correlate closely with increasing cancer volume. It is important to explore the relationship of microcarcinomas to these larger clinically significant cancers by comparing their histologic features and to trace their relationship to dysplasia, a proposed precursor lesion.
METHODS: The histologic features of 107 microcarcinomas were related to associated dysplasia lesions. Their histologic grade was quantitated and compared with the quantitative grade and volume distribution of 100 incidental autopsy cancers and 209 clinical cancers from radical prostatectomy.
RESULTS: Microcarcinomas were contiguous with dysplasia foci in 81% of the cases, and evidence of cancer origin was found in 48%. Only 3 of 107 microcarcinomas had Grade 4 (poorly differentiated) areas. Grade 4 frequency and extent increased with cancer volume, and the relationship was similar between the autopsy and prostatectomy series. Metastasis was found only with cancers larger than 4 cc and having Grade 4 areas.
CONCLUSIONS: The majority of prostatic microcarcinomas appeared to arise from dysplasia. Only 3% of these early cancers showed areas of high histologic grade. In the autopsy and clinical series, it appeared that poorly differentiated areas evolve from low-grade cancer with time and increasing volume. Probability of metastasis was a function of volume and grade.

Entities:  

Mesh:

Year:  1993        PMID: 8428349     DOI: 10.1002/1097-0142(19930201)71:3+<984::aid-cncr2820711415>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.

Authors:  I Leav; K M Lau; J Y Adams; J E McNeal; M E Taplin; J Wang; H Singh; S M Ho
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.

Authors:  Kosuke Miyai; Mukul K Divatia; Steven S Shen; Brian J Miles; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

3.  Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.

Authors:  I Kraljić; K Kovacić; M Tarle
Journal:  Urol Res       Date:  1994

4.  Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer.

Authors:  Eva Shrestha; Jonathan B Coulter; William Guzman; Busra Ozbek; Megan M Hess; Luke Mummert; Sarah E Ernst; Janielle P Maynard; Alan K Meeker; Christopher M Heaphy; Michael C Haffner; Angelo M De Marzo; Karen S Sfanos
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-10       Impact factor: 11.205

5.  Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy.

Authors:  A E Bogden; D LePage; S Zwicker; W Grant; M Silver
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.